THC
Tenet Healthcare Corporation · Healthcare · Medical - Care Facilities
Momentum-inputs (vergelijkbare managers):
breedte van houders +5.9% ·
aandelenstroom +7.8% ·
netto nieuwe posities +5.6%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 138 | +1 | 64.57M | $12.08B | +9 | −8 |
| Q1 2026 | 140 | -6 | 67.35M | $12.71B | +5 | −12 |
| Q4 2025 | 146 | 0 | 74.52M | $14.80B | +2 | −1 |
| Q3 2025 | 23 | 0 | 47.80M | $9.71B | — | −1 |
| Q2 2025 | 21 | 0 | 49.65M | $8.73B | +1 | −1 |
| Q1 2025 | 18 | +1 | 24.64M | $3.31B | +1 | — |
| Q4 2024 | 17 | -2 | 22.85M | $2.89B | — | −2 |
| Q3 2024 | 18 | 0 | 21.19M | $3.52B | — | — |
| Q2 2024 | 18 | — | 23.95M | $3.19B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 7.60M | +6.5% | $1.02B | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 7.60M | +6.5% | $1.02B | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Glenview Capital ✦ | 3.39M | +19.7% | $456.61M | 11.3% | ▲ Add | 4 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passief) | 3.02M | +1.0% | $406.14M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passief) | 2.20M | +4.0% | $296.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 2.20M | +4.0% | $296.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 1.87M | +643.2% | $251.05M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 8 | Norges Bank ✦ (passief) | 1.45M | -4.4% | $194.42M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 1.24M | +201.2% | $166.25M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 1.19M | -33.0% | $159.89M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 903.27K | +3.6% | $118.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 903.27K | +3.6% | $118.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 903.27K | +3.6% | $118.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 903.27K | +3.6% | $118.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 903.27K | +3.6% | $118.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 728.26K | -28.4% | $97.95M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 728.26K | -28.4% | $97.95M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 469.53K | +111.3% | $63.15M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 199.98K | -50.9% | $26.90M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 20 | Marshall Wace ✦ | 193.50K | -61.3% | $26.03M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Point72 Asset Management ✦ | 108.58K | Nieuw | $14.60M | 0.0% | New | 1 | SEC ↗ |
| 22 | Renaissance Technologies ✦ | 35.26K | -92.0% | $4.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 25.85K | -90.0% | $3.48M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 21.30K | -81.3% | $2.87M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | Harris Associates (Oakmark) ✦ | 2.40K | -29.4% | $322,800 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Point72 Asset Management | $14.60M | 0.0% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 686 houders, 81.68M aandelen, $13.63B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 2.50K aand · $652,075
Director · 4.92K aand · $1.30M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie